While genetic variants such as TβRI*6A have shown associations with BC risk and progression, the regulatory mechanisms and functional implications of TβRI and SMAD signaling in BC require further investigation for a comprehensive understanding of their potential as therapeutic targets. This evidence concerns the gene TGFBR1 and breast cancer.